Key Highlights:
– Aranscia, a global leader in clinical workflow and diagnostic technology solutions, has announced the strategic acquisition of Spesana, a top-tier provider of patient navigation, clinical collaboration, and oncology decision support tools.
– Carla Balch, Spesana’s Founder and CEO and a recognized leader in healthcare and oncology information systems, will take on the role of Executive Director across all Aranscia software platforms. In this role, she will oversee the continued commercial and technical growth of Spesana’s offerings.
Spesana: Advancing Precision Medicine Through Smart Clinical Tools
Founded in 2019, Spesana has built a healthcare platform designed to enhance the speed, efficiency, and impact of precision medicine initiatives. Currently in use at over 140 clinical sites, the platform delivers a robust suite of tools, including:
-
Patient navigation
-
Prior authorization support
-
Clinical trial collaboration features
-
Diagnostic workflow optimization
Spesana’s intelligent platform is trusted by a diverse client base that includes leading payers, multi-site healthcare providers, oncology networks, and diagnostic labs. Users have reported a 60% increase in the appropriate use of precision diagnostics—attributed to reduced administrative burden and clearer clinical processes.
Strategic Fit with Aranscia’s Precision Care Ecosystem
Spesana will join Aranscia’s growing portfolio of companies that are united by a common mission: to close clinical workflow gaps and expand access to precision care. Aranscia’s current portfolio includes:
-
2bPrecise – Known for EMR-integrated, lab-agnostic solutions that accelerate the adoption of precision medicine.
-
YouScript – A pioneer in real-time, personalized medication risk management and pharmacogenomics (PGx).
-
AccessDx Laboratory – A nationally certified molecular diagnostics lab specializing in PGx and personalized testing.
Carla Balch to Spearhead Software Strategy and Innovation
Carla Balch’s leadership is a central element of this acquisition. With a track record of innovation in oncology technology, she previously served as:
-
CEO of Altos Solutions, creators of OncoEMR (later acquired by Flatiron Health/Roche)
-
President of Nantcare, a tech-focused oncology and clinical trials firm
-
CEO of Inteliquet, a clinical trial matching platform acquired by IQVIA
She also serves on the Healthcare Council of the Federal Reserve Bank of St. Louis, bringing deep industry insight to Aranscia’s next phase of growth.
